The role of histologic grading in the prognosis of patients with carcinoma of the breast: Is this a neglected opportunity?

Cancer

Volumn 80, Issue 9, 1997, Pages 1708-1716

  Roberti, Nicholas E ^a  

^a NONE   (United States)

Author keywords

Breast neoplasms; Grade; Histopathology; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; METHODOLOGY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 0030666779     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1708::AID-CNCR3>3.0.CO;2-A     Document Type: Review

References (80)

1. Greenough RB. Varying degrees of malignancy in cancer of the breast. J Cancer Res 1925;9:453-63.
2. Patey DH, Scarff RW. The position of histology in the prognosis of cancer of the breast. Lancet 1928;1:801-4.
3. Bloom HJG. Prognosis in cancer of the breast. Br J Cancer 1950;IV:259-88.
4. Bloom HJG. Further studies on prognosis of breast carcinoma. Br J Cancer 1950;IV:345-67.
5. Bloom HJG, Richardson WW. Histologic grading and prognosis in breast cancer. Br J Cancer 1957;XI:359-77.
6. Bloom HJG, Field JR. Impact of tumor grade and host resistance on survival of women with breast cancer. Cancer 1971;28:1580-9.
7. Black MM, Opler S, Spear F. Survival in breast cancer in relation to structure of the primary tumor and regional lymph nodes. Surg Gynecol Obstet 1955;100:543-51.
8. Majmudar BN, James AG, Holaday WJ. Relationship of tumor grade, stage and host response in a group of breast neoplasms. Cancer 1971;28:1188-94.
9. Fisher ER. The pathologist's role in the diagnosis and treatment of breast cancer. Surg Clin North Am 1978;58:705-21.
10. Fisher ER, Redmond C, Fisher B. Histologic grading of cancer. Pathol Annu 1980;15:239-51.
11. Fisher ER, Redmond C, Fisher B, and participating NSABP investigators. Pathologic findings from the NSABP. VIII. Relationship of chemotherapeutic response to tumor differentiation. Cancer 1983;51:181-91.
12. Fisher ER, Sass R, Fisher B, and collaborating NSABP investigators. Pathologic findings from the NSABP (protocol #4). X. Discriminants for 10th year treatment failure. Cancer 1984;53:712-23.
13. Parl FF, DuPont WD. A retrospective cohort study of histologic risk factors in breast cancer patients Cancer 1982; 50:2410-6.
14. Hutter RVP. Pathologic parameters useful in predicting prognosis for patients with breast cancer. Monogr Pathol 1984;25:175-85.
15. Davis BW, Gelber RD, Goldhirsch A, Hartman WH, Locher GW, Reed R, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastases. Cancer 1986;58:2662-70.
16. Contesso G, Jotti GS, Bonadonna G. Tumor grade as a prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol 1989;25:103-9.
17. Hacene K, LeDoussal V, Rouesse J, Brunet M. Predicting distant metastases in operable breast cancer patients. Cancer 1990;66:2034-40.
18. Wolman SR, Feiner HD, Schenella RA, Gimotti P, Ownby H, Maloney T, et al. A retrospective analysis of breast cancer based on outcome differences. Hum Pathol 1991;22:475-80.
19. Clayton F. Pathologic correlates of survival in 378 node-negative infiltrating ductal breast carcinomas. Cancer 1991;68:1309-17.
20. Aaltomaa S, Lipponen P, Eskelinen M, Alhava E, Syrjanen K. Nuclear morphology and mitotic indexes as prognostic factors in breast cancer. Eur J Surg 1991;157:319-24.
21. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Mari S, Alhava E, et al. Histologic assessments of the prognostic factors in female breast cancer. Oncology 1992;49:1-8.
22. Bunting JS, Hemsted EH, Kremer JK. The pattern of spread and survival in 596 cases of breast cancer related to clinical staging and histologic grade. Clin Radiol 1976;27:9-15.
23. Syrjanen KJ, Hjelt LH. Tumor-host interrelationships in carcinoma of the female breast. Surg Gynecol Obstet 1978; 147:43-8.
24. Freedman LS, Edwards DN, McConnell EM, Downham DY. Histologic grade and other prognostic factors in relationship to survival in patients with breast cancer. Br J Cancer 1979;40:44-54.
25. Mitchell RE, Mitchell RM, Shugg D, Wyld C. The prognosis of breast cancer based on histologic assessment. Aust NZ J Surg 1979;49:305-12.
26. Nikkanen V, Mikko L, Toikkanen S. Treatment results in mammary carcinoma stages I-IV. Acta Radiol Oncol 1981;20:9-18.
27. Elston CW, Gresham GA, Rao GS, Zebro T, Haybittle JL, Houghton J, et al. The cancer research campaign (King's Cambridge) trial for early breast cancer: clinico-pathological aspects. Br J Cancer 1982;45:655-69.
28. Stewart JF, Rubens RD, Millis RR, Kink IB, Hayward JL. Steroid receptors and prognosis in operable (Stage I and II) breast cancer. Eur J Cancer Clin Oncol 1983;19:1381-7.
29. Elston CW. Assessment of histologic differentiation in breast cancer. Aust NZ J Surg 1984;54:11-5.
30. Ketterhagen JP, Quackenbush SR, Haushalter RA. Tumor histology as a prognostic determinant in carcinoma of the breast. Surg Gynecol Obstet 1984;158:120-3.
31. Blanco G, Alavaikko M, Ojala A, Collan Y, Heikkinen M, Hietenan T, et al. Estrogen and progesterone receptors in breast cancer: relationships to tumor histopathology and survival of patients. Anticancer Res 1984;4:383-9.
32. Calle R, Viloq JR, Zafrani B, Vielh P, Forquet A. Local control and survival of breast cancer treated by limited surgery followed by radiation. Int J Radiat Oncol Biol Phys 1986;12:873-8.
33. Elston CW, Ellis IO. Pathologic prognostic factors in breast cancer. Histopathology 1991;19:403-10.
34. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 1991;68:2142-9.
35. Theissig F, Kunze KD, Haroske G, Meyer W. Histologic grading of breast cancer. Interobserver reproducibility and prognostic significance [abstract]. Pathol Res Pract 1990; 186:732-6.
36. Schumaker M, Schmoor C, Sauerbrei W, Schauer A, Ummenhoffer L, Gatzmeier W, et al. The prognostic effect of histologic tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 1993;25:235-45.
37. McGrath PC, Holley DT, Hamby LS, Powell DE, Mattingly C, Freeman JW. Proliferation-associated nucleolar antigen P120: a prognostic marker in node-negative breast cancer. Surgery 1994;116:616-20.
38. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstenson B, Mouridsen HT. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cooperative Group (DBCG) Breast Cancer Res Treat 1994;32:281-90.
39. Bloom HJG. The natural history of untreated breast cancer. Ann NY Acad Sci 1964;742-5.
40. Dawson PJ, Ferguson DJ, Karrison T. The pathologic findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer 1982;50:2131-8.
41. Fentimen IS, Cuzick J, Millis RR, Hayward JL. Which patients are cured of breast cancer? BMJ 1984;289:1108-11.
42. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast cancer. Cancer 1993;71:1780-90.
43. Stierer M, Rosen HR, Weber B, Marczell A, Komek GV, Czerwenka E. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than 1 centimeter. Surg Gynecol Obstet 1992;175:151-9.
44. Sauer R, Schauer A, Raushecker HF, Schumaker M, Gatzemeyer W, Sauerbrei J, et al. Breast preservation versus mastectomy in early breast cancer-1991 update of the GBSG1-protocol and prognostic factors. Strahlenth Onkol 1992; 168:191-202.
45. Solin LJ, Yeh IT, Kurtz J, Fourquet A, Recht A, Kuske R, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive radiation. Cancer 1993;71:2232-42.
46. White J, Levine A, Gustafson G, Winbish K, Ingold J, Pettinga J, et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1995;31(4):791-7.
47. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995;345:1154-7.
48. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, et al. Ten year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995;31A:1425-7.
49. Rosner D, Lane WE. Node negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant treatment. Cancer 1990;66:199-205.
50. Spaulding CA, Goldstein G, Morrison G, Holthaus W, Garber B. Node-negative breast carcinoma treated without adjuvant therapy. South Med J 1992;85:355-64.
51. Johnson H, Mazood S, Belluco C, Abou-Azama AM, Dee S, Kahn L, et al. Prognostic factors in node-negative breast cancer. Arch Surg 1992;127:1386-91.
52. Merson M, Andreola S, Galimberti V, Buffalino R, Marchini S, Veronese U. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 1992;70:504-8.
53. Theissig F, Dimmer V, Haroske G, Kunze KD, Meyer W. The use of nuclear image cytometry, histologic grading and DNA cytometry to make breast cancer prognosis more objective. Anal Cell Pathol 1991;3:351-60.
54. Mansour EG, Ravdin PM, Dressier L. Prognostic factors in early breast cancer. Cancer 1994;74:381-400.
55. Fisher ER, Redmond C, Fisher B, and Others for the National Surgical Adjuvant Breast and Bowel project investigators. Prognostic factors in NSABP studies of women with node-negative breast cancer. Monogr Natl Cancer Inst 1992; 11:151-8.
56. Dalton LW, Page DL, DuPont WD. Histologic grading of breast cancer. A reproducibility study. Cancer 1994;73:2765-70.
57. Frierson HF Jr., Wolber RA, Berean KW, Frankquemont DW, Gaffey MJ, Boyd JC, et al. Interobserver reproducibility of the Nottingham modification of the Bloom-Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;103:195-8.
58. Robbins P, Pinder S, deKlerk N, Dawkins H, Harvey J, Sterrett G, et al. Histologic grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;26:873-9.
59. Fisher B, Redmond C, Fisher E, Caplan R, and other contributing National Surgical Adjuvant Breast and Bowel Project investigators. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-87.
60. McGuire WL. Estrogen receptor vs. nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 1988;6:1071-2.
61. Merkle DE, Winchester DJ, Goldschmidt RA, August CZ, Wruck DM, Rademaker AW. DNA flow cytometry and pathologic grading as prognostic guides in axillary node-negative breast cancer. Cancer 1993;72:1926-32.
62. Estaban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE. Prognostic relevance of carcinoembrionic antigen and estrogen receptor status in breast cancer patients. Cancer 1994;74:1575-83.
63. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;36:283-91.
64. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, et al. Prognostic value of P53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71-81.
65. Ciatto S, Bonardi R, Bianchi S. Nuclear grading and prognosis in node negative breast cancer. Neoplasma 1992;39:167-70.
66. Ducatman BS, Emery ST, Wang HH. Correlation of histologic grade of breast cancer with cytologic features on fine-needle aspiration of the breast. Mod Pathol 1993;6:539-43.
67. Howell LP, Gandour-Edwards R, O'Sullivan D. Application of the Scarff-Bloom-Richardson tumor grading system to fine-needle aspirates of the breast. Am J Clin Pathol 1994;101:262-5.
68. Robinson IA, McKee G, Nicholson A, D'Arcy J, Jackson PA, Cook MG, et al. Prognostic value of cytologic grading of fine-needle aspirates from breast carcinomas. Lancet 1994; 343:947-9.
69. Report of the Council of Scientific Affairs AMA. Management of patients with node-negative breast cancer. Arch Intern Med 1993;153:58-67.
70. Clark RM, McCulloch PB, Levine MN, Lipa M, Wilkinson RH, Mahoney LJ, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 1992;84:683-9.
71. Figueroa JA, Yee D, McGuire WL. Prognostic indicators in early breast cancer. Am J Med Sci 1993;305:176-82.
72. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campell FC, et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-5.
73. Clark GM, Sledge GW, Osborn CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987;5:55-61.
74. The Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988;319:677-83.
75. The Ludwig Breast Cancer Study Group. Prolonged disease free survival after one course of perioperative chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491-6.
76. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytoxic, or immune therapy. Parts I and II. Lancet 1992;339:1-15, 71-84.
77. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. The natural history of node-negative breast cancer. J Clin Oncol 1995;13:1114-51.
78. Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen. Cancer 1996;77:683-90.
79. Moss TM. Therapeutic Radiology. St Louis: C.V. Mosby, 1959.
80. American Joint Committee on Cancer. Manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott, 1992.